If You Hate (Or Love) The ‘Mag 7' There Is An ETF To Profit

The article compares two ETF approaches to Magnificent Seven exposure: Roundhill Magnificent Seven ETF (MAGS), with a 0.30% expense ratio, about $3.8 billion in assets, a 0.01% 30-day median bid-ask spread, and a 1.48% 30-day SEC yield; and Defiance Large Cap ex-MAG7 ETF (XMAG), with a 0.35% expense ratio and a 0.37% bid-ask spread. MAGS offers equal-weight exposure to Microsoft, Apple, Alphabet, Amazon, Meta, Nvidia, and Tesla, while XMAG excludes those names and leaves Broadcom as the largest holding at 4.28%. The piece is broadly neutral and educational, with a cautious tone about concentration risk and AI-fueled valuation enthusiasm.

Analysis

The key second-order effect is not just higher concentration, but a subtle redistribution of ownership from passive beta into more explicit factor bets. MAGS effectively turns the Magnificent Seven into a concentrated, low-friction momentum vehicle, while XMAG creates a cleaner “rest-of-market” basket that should behave better if breadth improves or if the mega-cap premium compresses. That makes the trade less about whether these firms are good businesses and more about whether earnings and capex expectations can keep outrunning the market’s tolerance for duration risk.

The market’s bigger vulnerability is capex saturation. If AI infrastructure spend keeps rising faster than near-term monetization, the winners may shift from the platform companies to the picks-and-shovels ecosystem: semis, networking, power management, and data-center infrastructure. Broadcom is an important tell here; in an ex-MAG7 structure it becomes a quasi-leader, which means capital is likely to leak from the “core seven” into adjacent beneficiaries even if the megacaps continue to report strong headline numbers.

The contrarian risk on the avoidance trade is that excluding the seven may create a structural underperformance problem in a regime where a narrow group keeps compounding earnings and buybacks. The contrarian risk on the concentration trade is that equal-weighting still leaves investors exposed to a shared factor shock: if rates back up, AI returns disappoint, or capex discipline becomes a concern, all seven can de-rate together over a 3-12 month horizon. Liquidity matters too: wider spreads and lower capacity in the ex-MAG7 wrapper make it more vulnerable to flow-driven dislocations around month-end and quarter-end rebalances.

The cleanest tell is breadth versus leadership. If equal-weight S&P underperforms cap-weight by another few hundred bps while semis and data-center suppliers hold bid, the market is saying this is still a narrow capex cycle, not a healthy broad bull market. If breadth starts to catch up, XMAG should outperform as the market rotates into underowned cyclicals, financials, and healthcare, especially if earnings revisions outside megacap tech stabilize over the next 1-2 quarters.

Key Decisions for Investors

• Use MAGS as a tactical momentum overlay, not a core holding: initiate on pullbacks to the 50-day average, target a 6-10% upside move over 1-2 months, and keep a tight 5% stop if rates or AI sentiment turn.
• Pair trade: long XMAG / short QQQ for a 1-3 month breadth recovery setup. This works best if megacap tech stalls while financials, healthcare, and industrials continue to see positive revisions; risk is a renewed AI-led squeeze.
• Own beneficiaries of AI capex rather than the capex spenders: long AVGO versus a basket of the seven via MAGS. AVGO has cleaner monetization of the buildout and less balance-sheet intensity; use a 3-6 month horizon.
• If positioning data show crowded long exposure in MAGS, buy downside protection via MAGS put spreads around the next earnings window. The goal is to hedge a 7-12% de-rating if capex guidance disappoints.
• Avoid outright shorting the seven as a basket; instead, express skepticism through relative-value underweights versus XMAG, since single-name shorts are vulnerable to index flows and buyback support.